IRCT2015012519567N1.

Trial name or title	Comparison of pulsed actinomycin versus 5‐day methotrexate for the treatment of low‐risk gestational trophoblastic disease in patients
Methods	Randomised single‐blind trial in Iran
Participants	44 women with WHO risk score 0‐6
Interventions	Arm 1: Actinomycin 1.25 mg/m2 every 14 days IV (maximum dose 2 mg) Arm 2: MTX 5‐day (0.4 mg/kg IV) (25 mg max)
Outcomes	Primary: BhCG
Starting date	21‐3‐2011. Estimated completion date 20‐3‐2015
Contact information	Dr Abbaslou: fabbaslou@yahoo.com; mirzalib@sina.tums.ac.ir
Notes	Investigators emailed 28/3/16 to enquire about completion (no response received)